Ex vivo gene therapy based vaccine with nucleic acid molecule encoding for cd70 for the treatment of b-cell malignancies

The present invention relates to a method of treating a B-cell malignancy in a subject using a vaccine composition comprising a population of malignant B cells from said subject transformed with a nucleic acid molecule encoding for a CD70 polypeptide. Epstein-Barr virus (EBV) infection in humans is a major trigger of malignant and non-malignant B cell proliferations. The inventors showed that EBV-specific T lymphocytes cannot expand properly when stimulated with CD70-deficient EBV-infected cells, while expression of CD70 restores expansion. In particular, the present invention relates to a method of treating a B-cell malignancy in a subject in need thereof comprising i) providing a sample of malignant B cells obtained from the subject ii) isolating and culturing a population of malignant B cells from the sample of step i), iii) introducing in the population malignant B cells of step ii) a nucleic acid molecule encoding for a CD70 polypeptide and iv) administering to the subject a therapeutically effective amount of the population of malignant B cells of step iii).

Keywords: B-malignancies, CD70, CD27, cell therapy ,B leukemia, lymphoma, Epstein-Barr virus, Vaccine, ex vivo gene therapy
Patent Application number: EP16305471.1
Inventors:
Alain FISCHERKazushi IZAWAEmmanuel MARTINSylvain LATOUR
Publications:
J Exp Med. 2017 Jan;214(1):73-89. doi: 10.1084/jem.20160784. Epub 2016 Dec 23.

Reference:

BIO16135-T1

Business Developper
contact
Elodie Acloque
Elodie Acloque
Business Developer
Patent filling date: 22-04-2016

You might also be interested in